Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06927999Phase 2Recruiting

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Role: lead

NCT05363670Phase 2Completed

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Role: lead

NCT06834165Phase 4Recruiting

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

Role: lead

NCT05496465Phase 2Completed

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Role: lead

NCT04930900Phase 1Completed

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

Role: lead

All 5 trials loaded